Literature DB >> 2641112

[Value of vitrectomy in intermediate uveitis and Behçet's disease with hyalitis. A study of 400 cases].

S Limon, J Renard, G Waligora, M Mokrane.   

Abstract

Can vitrectomy help to understand the vitreous role in intermediate uveitis and Behçet's disease with vitritis without retinal detachment? 400 vitrectomies were decided because of vitreous changes but, over all, if macular changes were seen clinically or on the angiogram in 58 Behçet's disease and 342 intermediate uveitis including 59 children cases. Visual acuity, clinical, angiographical and visual field controls, recurrences, reduction of the medical treatment and growth were followed during 1 to 9 years. The vitrectomy products were compared to those of other inflammatory origin vitreous, the both representing 149 cases. Vitrectomy at the early stage of only posterior interface changes prevent the macular edema but this one is irreversible. The preexisting angiographical lesions have not regressed but they are generally quiet. The RD incidence is lower even if it is possible after vitrectomy, in 1.2% of the cases (1% in late vitrectomies). Recurrences and further medical treatment are reduced. This psychological point of view is important. Thus, vitrectomy at alone posterior interface change stage avoid ocular complications. Its pathogenic role in intermediate uveitis is not demonstrated; it seems more a secondary than a primary process.

Entities:  

Mesh:

Year:  1989        PMID: 2641112

Source DB:  PubMed          Journal:  Ophtalmologie        ISSN: 0989-3105


  3 in total

1.  Pars plana vitrectomy in ocular Behçet's disease.

Authors:  M Soylu; N Demircan; A Pelit
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

2.  Therapeutic pars plana vitrectomy for chronic uveitis: a retrospective study of the long-term results.

Authors:  H Verbraeken
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-05       Impact factor: 3.117

3.  Long-term results of pars plana vitrectomy in the management of complicated uveitis.

Authors:  A Heiligenhaus; N Bornfeld; M H Foerster; A Wessing
Journal:  Br J Ophthalmol       Date:  1994-07       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.